QPPV.COM KNOWLEDGE ASSESSMENT

EU Marketing Authorisation Knowledge Assessment

Test your understanding of the concepts covered by What Is a Marketing Authorisation in the EU?.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which scenario is characteristic of the mutual recognition procedure?

A product has no national authorisation and seeks simultaneous authorisation in several Member States An existing national assessment is relied upon to seek recognition in other Member States A single application is assessed by CHMP for a Union-wide authorisation A product is supplied commercially without any national authorisation

Question 2 of 10 What is the most appropriate interpretation of residual uncertainty at the time of initial authorisation?

It necessarily proves that the original authorisation was inappropriate It can be managed through continuing evidence generation and regulatory oversight It means that the product information cannot contain any conditions of use It eliminates the need for routine pharmacovigilance

Question 3 of 10 What is the key regulatory difference between a conventional generic application and a biosimilar application?

A biosimilar application concerns a biological reference medicine and uses a tailored comparability assessment A generic application always requires a completely new clinical development programme Biosimilars are authorised without assessing quality, safety or efficacy Generics and biosimilars use identical evidence requirements because both rely on reference products

Question 4 of 10 Which interpretation most accurately describes an EU marketing authorisation?

A permanent declaration that a medicine is safe for all patients A legally defined permission to market a particular medicinal product under specified conditions A commercial decision confirming that a product will be supplied in every Member State A scientific publication summarising the medicine's clinical development

Question 5 of 10 Which statement correctly distinguishes marketing authorisation from market access?

Marketing authorisation automatically guarantees reimbursement and procurement Market access is limited to the scientific assessment of quality, safety and efficacy Marketing authorisation establishes regulatory permission to market, while market access may involve pricing, reimbursement, HTA and procurement The two concepts are interchangeable in all EU Member States

Question 6 of 10 Which CTD module contains detailed clinical study reports supporting efficacy and clinical safety?

Module 1 Module 2 Module 4 Module 5

Question 7 of 10 A company wants to change an authorised manufacturing site for commercial reasons. What is the most appropriate first regulatory principle?

The company may implement the change immediately because it does not affect the indication The company should determine the applicable variation or other regulatory procedure before implementing the change The change requires a completely new marketing authorisation in every case Manufacturing-site changes are outside the scope of the marketing authorisation

Question 8 of 10 Why should a regulatory conclusion about one product not automatically be applied to another product containing the same active substance?

Because active substances have no relevance to regulatory assessment Because products may differ in form, strength, route, formulation, indication or population Because only centrally authorised products can be compared Because products with the same active substance must always have identical benefit-risk balances

Question 9 of 10 Which conclusion is most accurate when a medicine receives a marketing authorisation despite known adverse effects?

The regulator has concluded that the adverse effects are unrelated to the medicine The regulator has determined that the benefits outweigh the identified and remaining risks under specified conditions The adverse effects are considered acceptable only because post-authorisation monitoring is optional The product is considered risk-free for the authorised population

Question 10 of 10 Which sequence best represents the lifecycle perspective described in the article?

Commercial launch, permanent approval, no further regulatory assessment Pre-authorisation evidence, scientific assessment, legal decision, post-authorisation evidence and possible reassessment Signal detection, clinical development, initial application and authorisation Manufacturing change, automatic approval, market access and then initial benefit-risk assessment

EU Marketing Authorisation Knowledge Assessment

Cookie Settings